Abstract
Autologous stem cell transplantation (ASCT) is an important component of treatment of multiple myeloma (MM). The post-ASCT setting offers a unique opportunity to increase myeloma specific immunity through enhancement of T and NK cell responses. The vast array of therapeutics being developed for MM, including cell-based therapies, dendritic vaccines, bispecific antibodies, and IL-15 agonists, provide the opportunity to increase tumor-specific immunity. Maintenance therapies, including immunomodulatory drugs, proteasome inhibitors, and daratumumab, exhibit a significant anti-myeloma response by modulating the immune system. Lenalidomide promotes an antitumoral immune microenvironment, whereas daratumumab can potentially cause NK cell fratricide. Thus, understanding the effects of commonly used maintenance drugs on the restoration of tumor specific immunity is important. In this review, we look at current and emerging therapeutics and their integration post-ASCT in the context of immune reconstitution to improve clinical responses in patients with MM. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 61-69 |
| Number of pages | 9 |
| Journal | Transplantation and Cellular Therapy |
| Volume | 28 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2022 |
Bibliographical note
Funding Information:Financial disclosure: M.J. has received clinical research funding from Nektar Therapeutics and Fate Therapeutics and honoraria from Kyowa Kirin and Bristol Meyers Squibb. VB has research funding from Incyte, BMS, Gamida Cell, Dr.Reddy and FATE Therapeutics. VB is an Advisory Board member for Novartis, Karyopharma and Gamida.
Publisher Copyright:
© 2021
Keywords
- Bispecific antibodies
- CARNK
- CART
- Immune reconstitution
- Multiple myeloma
PubMed: MeSH publication types
- Journal Article
- Review